| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.06 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.06 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.06 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.06 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.06 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | -0.066 | 0.06 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.06 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.07 | 0.06 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.068 | 0.06 |